- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
C7orf20 Antibody (C-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | ||||
| AP9611b | DISCONTINED INQUIRE CLICK INQUIRE Add to cart | |||
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
C7orf20 Antibody (C-term) - Product info | |
| Application | WB
|
| Primary Accession | Q7L5D6 |
| Other Accession | Q9D1H7, Q0P5I8 |
| Reactivity | Human, Mouse |
| Predicted | Bovine |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 36504 Da |
C7orf20 Antibody (C-term) - Additional info | |
| Gene ID 51608 | |
| Other Names GET4; C7orf20; CEE; TRC35; Golgi to ER traffic protein 4 homolog; Conserved edge-expressed protein; Transmembrane domain recognition complex 35 kDa subunit | |
| Target/Specificity This C7orf20 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 259~288 amino acids from the C-terminal region of human C7orf20. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions C7orf20 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
C7orf20 Antibody (C-term) - Protein Information | |
| Name GET4 | |
| Synonyms C7orf20, CEE, TRC35 | |
| Function Component of the BAT3 complex, a multiprotein complex involved in the post-translational delivery of tail-anchored (TA) membrane proteins to the endoplasmic reticulum membrane. TA membrane proteins, also named type II transmembrane proteins, contain a single C-terminal transmembrane region. The complex acts by facilitating TA proteins capture by ASNA1/TRC40: it is recruited to ribosomes synthesizing membrane proteins, interacts with the transmembrane region of newly released TA proteins, and transfers them to ASNA1/TRC40 for targeting | |
| Cellular Location Cytoplasm, cytosol. | |
C7orf20 Antibody (C-term) - Related products
AP9611b: C7orf20 Antibody (C-term)
C7orf20 Antibody (C-term) - Application data
-
Western blot analysis of C7orf20 Antibody (C-term) (Cat. #AP9611b) in mouse cerebellum tissue lysates (35ug/lane). C7orf20 (arrow) was detected using the purified Pab.
C7orf20 Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
CEE (Conserved edge expressed protein) belongs to the UPF0363 family.
REFERENCES
Chang, Y.W., et al. J. Biol. Chem. 285(13):9962-9970(2010) Fernandes, J.M., et al. Genomics 91(4):315-325(2008)
